2016-2018年南京地区调脂药物利用分析  

Application analysis of lipid-modulating agents in Nanjing area from 2016 to 2018

作　　者：蔡俊[1] 韩舟 刘梦颖[1] 朱巧玲 刘慧[1] 李俐[1] CAI Jun;HAN Zhou;LIU Meng-ying;ZHU Qiao-ling;LIU Hui;LI Li(Department of Pharmacy,Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《临床药物治疗杂志》2020年第8期33-38,共6页Clinical Medication Journal

基　　金：江苏省药学会-天晴医院药学基金(项目编号:Q2019024);南京药学会-常州四药医院药学科研基金(项目编号:2019YX016)。

摘　　要：目的分析江苏省南京地区2016-2018年调脂药物使用情况,为合理使用调脂药物提供参考。方法使用用药金额、用药频度(DDDs)、限定日费用(DDC)、排序比(B/A)对南京地区55家医院调脂药物进行统计分析。结果2016-2018年,南京地区调脂药物用药金额和DDDs均逐年递增,复合年增长率(CAGR)分别为12.51%和17.46%。在24种调脂药物用药金额和DDDs排序中,阿托伐他汀、瑞舒伐他汀、依折麦布、血脂康稳居前4位,且阿托伐他汀和瑞舒伐他汀占据绝对优势。多廿烷醇、降脂灵和保利尔的DDC排序前3位。多数调脂药物的B/A值接近1。结论南京地区调脂药物使用合理,药物使用集中在他汀类,其中阿托伐他汀和瑞舒伐他汀是最常用的品种。Objective This study was designed to analyze the application of lipid-modulating agents in Nanjing from2016 to 2018 and provide reference for rational use of lipid-modulating agents.Methods Consumption sum,defined daily dose(DDDs),defined daily cost(DDC)and B/A were used to analyze the usage of lipid-modulating agents at 55 hospitals in Nanjing area.Results From 2016 to 2018,consumption sum and DDDs of lipid-modulating agents in Nanjing area increased year by year,with Compound Annual Growth Rates(CAGR)of 12.51%and 17.46%,respectively.Among the 24 kinds of medications,atorvastatin,rosuvastatin,ezetimibe and xuezhikang ranked astop 4,and atorvastatin and rosuvastatin were dominant.DDCs of docosanol,jiangzhiling and baolier ranked as top 3.The B/A values of most lipid-modulating agents were close to 1.Conclusion The use of lipid-modulating agents in Nanjing area was reasonable,and statins are the preferred agents,among which atorvastatin and rosuvastatin were the most common species.

关 键 词：调脂药物 南京地区 利用分析 

分 类 号：R972.6[医药卫生—药品]